Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Approves Revision to Kitasato Daiichi Sankyo Vaccine’s Management Resource Reuse Plan
July 25, 2012
- PAFSC’s First Committee to Review 4 Products Including Lotriga from Takeda on August 3
July 24, 2012
- PAFSC’s Second Committee Recommends Approval for Symbicort for COPD
July 24, 2012
- NIBIO to Play Important Role in Collaboration between Industry, Government, Academia: Director General Yamanishi
July 24, 2012
- Expert Panel Recommends Priority Measures Including Pediatric Drug Development for FY2013 Budget
July 23, 2012
- Mix of Differential Pricing and Generic Drug Use Promotion Policies Can Help Reduce Drug Expenditure: Prof. Sakamaki
July 23, 2012
- MHLW Study Group Launches Info Website on Epilepsy Treatment Facilities
July 23, 2012
- Vaccines Are Good Investments: Dr Warton of CDC
July 23, 2012
- Industry Representatives Express Concern over Large Reductions in Prices of Long-Listed Drugs at CSIMC
July 20, 2012
- Industry Figures Stress Positive Impact of Premium for Generic-Name Prescribing at CSIMC
July 20, 2012
- Cost-Effective Assessments to Be Limited to Technologies for Which Alternatives Are Available: CSIMC
July 19, 2012
- PAFSC’s 2nd Committee on Drugs to Review 2 Combination DPT-IPV Vaccines on July 20
July 19, 2012
- Establishment of Relief System for Victims of Health Damage Due to Anticancer Drugs Should Be Put Off: MHLW Study Group
July 17, 2012
- Draft Revitalization Strategy Calls for Screening of 100 Drug Seeds through Drug Discovery Support Network by FY2015
July 13, 2012
- PFSB Calls for Revisions of Package Inserts for 13 Products Including Ranmark, Lyrica
July 13, 2012
- Gov’t to Discuss Expansion of Japan-EC Mutual Recognition Agreement in Pharmaceutical Sector
July 12, 2012
- Health Minister Komiyama Takes Lead to Include Reference Price Systems in Policy-Screening Group’s Proposals
July 10, 2012
- MHLW’s Medical Innovation Promotion Office Sets Up Cross-Sectional Task Forces to Discover Innovative Anticancer Drugs
July 10, 2012
- Bill Payers, Healthcare Providers Fighting over Financial Resources from Price Cuts for Long-listed Drugs
July 10, 2012
- PAFSC Second Committee to Review Products Including Novartis’s Pulmonary Infection Treatment on July 20
July 10, 2012
ページ
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…